Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:21:23 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:AUPH from 2023-05-04 to 2024-05-03 - 38 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 06:30U:AUPHSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-05-02 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
2024-05-01 06:00U:AUPHNews ReleaseAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
2024-04-30 06:00U:AUPHNews ReleaseThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS(TM) (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
2024-04-16 10:48U:AUPHNews ReleaseUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
2024-04-15 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
2024-04-09 06:00U:AUPHNews ReleaseAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
2024-02-29 08:30U:AUPHNews ReleaseAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
2024-02-27 08:30U:AUPHNews ReleaseAurinia to Participate in Upcoming Investor Healthcare Conferences
2024-02-15 06:16U:AUPHSEDAR MD & ASEDAR Annual Report
2024-02-15 06:04U:AUPHSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-02-15 06:00U:AUPHNews ReleaseAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
2024-02-05 08:30U:AUPHNews ReleaseAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
2024-01-05 06:00U:AUPHNews ReleaseAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
2023-12-20 06:00U:AUPHNews ReleaseAurinia Submits IND Application to US Food & Drug Administration for AUR 200
2023-11-13 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS ‚ ® (Voclosporin) in Japan
2023-11-07 10:30U:AUPHNews ReleaseAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS ¢ “ ‡ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
2023-11-02 18:00U:AUPHNews ReleaseAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS ¢ “ ‡ for Managing Lupus Nephritis
2023-11-02 06:24U:AUPHSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-02 06:23U:AUPHSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-02 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
2023-10-26 15:00U:AUPHNews ReleaseAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
2023-10-19 03:00U:AUPHNews ReleaseCORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
2023-10-13 12:00U:AUPHNews ReleaseAurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
2023-09-21 06:00U:AUPHNews ReleaseAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
2023-08-21 06:00U:AUPHNews ReleaseAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
2023-08-03 10:41U:AUPHSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-03 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
2023-07-20 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
2023-07-19 12:05U:AUPHNews ReleaseLong Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS ‚ ® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
2023-06-29 16:05U:AUPHNews ReleaseAurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
2023-06-20 09:00U:AUPHNews ReleaseAurinia Showcases Three Oral Presentations for LUPKYNIS ‚ ® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
2023-06-01 09:00U:AUPHNews ReleaseLUPKYNIS ‚ ® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
2023-05-26 17:16U:AUPHNews ReleaseAurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
2023-05-17 12:14U:AUPHNews ReleaseAurinia Announces 2023 Annual General Meeting Results
2023-05-09 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS ‚ ® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
2023-05-04 07:06U:AUPHSEDAR Interim Financial StatementsSEDAR MD & A
2023-05-04 06:00U:AUPHNews ReleaseAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results